Mode
Text Size
Log in / Sign up

Feasibility study finds time-restricted eating safe in PCOS with exploratory metabolic signalsCan time-restricted eating help people with PCOS lose weight safely?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider time-restricted eating a safe, feasible exploratory option in PCOS, pending larger efficacy trials.

This 24-week randomized crossover feasibility study assessed time-restricted eating (TRE) in participants with polycystic ovarian syndrome (PCOS). The study recruited 15 participants, with 11 completing the protocol. The intervention was an 18-hour fast/6-hour eating window for 12 weeks, compared to a 12-week ad libitum regimen. The primary outcome was not reported, as the study was not powered to detect changes in metabolic or anthropometric indices.

Exploratory secondary analyses showed statistically significant decreases in several measures during the TRE period. HbA1c decreased (p=0.04), weight decreased (p=0.001), BMI decreased (p=0.001), hip circumference decreased (p=0.05), and waist circumference decreased (p=0.001). Absolute numbers and effect sizes for these changes were not reported.

Regarding safety and feasibility, there were no serious adverse events in the TRE group. Compliance was near-total among participants who completed the intervention. Four participants dropped out due to commitment or study duration concerns. Key limitations include that the study was not powered to detect metabolic or anthropometric changes, there were considerable recruitment difficulties, and the sample size was very limited. Funding and conflicts of interest were not reported.

In practice, this study suggests TRE may be a safe and feasible intervention to explore in PCOS, but the metabolic signals are preliminary. The findings should be interpreted cautiously due to the study's exploratory nature and small size. Definitive conclusions about efficacy await larger, adequately powered trials.

People living with Polycystic Ovarian Syndrome (PCOS) often struggle with weight and blood sugar control. This small study asked if a specific eating schedule could help. Participants were asked to eat only within a six-hour window for 12 weeks, then switched to eating whenever they wanted for the next 12 weeks. The goal was simply to see if this approach was safe and doable for this group.

The results showed clear benefits for those who stayed in the program. Their weight, body mass index, and measurements around their hips and waists all went down. Blood sugar levels also improved. Most importantly, no serious safety problems occurred, and almost everyone who started the plan stuck with it.

But there is a catch. Only 11 people finished the entire study out of 15 who started. Researchers could not prove this method changes health markers for sure because the group was too small. While the approach seemed safe and easy to follow, these findings are just a first step. More research is needed before anyone can say this is a reliable treatment.

What this means for you:
Time-restricted eating was safe and helped weight in a small PCOS group, but results are early.

Study Details

Study typeRct
Sample sizen = 10
EvidenceLevel 2
Follow-up2.8 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: Time-restricted eating (TRE) represents a novel intervention that may improve hyperinsulinaemia and reduce weight, but has not been studied in polycystic ovarian syndrome (PCOS). In a randomised interventional study (NCT05126199 [1]), we investigated the feasibility of TRE in PCOS including recruitment, compliance, safety, drop-out rate, and effect on insulin-related parameters, anthropometrics, nutritional intake and metabolic indices. METHODS: Participants were randomised to a 12-week TRE regimen (18 h fast/6 h eating window) or 'ad libitum' regimen (no time-restriction), and then crossed over to the alternative regimen for a further 12 weeks. RESULTS: TRE was a feasible intervention with near-total compliance in those completing the intervention; however, there were considerable difficulties with recruitment. A total of 70 were eligible to participate, of which ultimately 15 were recruited, and 11 completed the study (4 [27%] drop-outs due to commitment/study duration). There were no serious adverse events in the TRE group. Compliance [%(SD)] with TRE was 94.7(4.5)%, and 10 participants were keen to continue the intervention post-study. Whilst the study was not powered to detect changes in metabolic or anthropometric indices, exploratory analysis showed a decrease in HbA1c (p = 0.04), weight (p = 0.001), BMI (p = 0.001), hip circumference (p = 0.05) and waist circumference (p = 0.001) in the TRE group compared to the ad libitum eating group. CONCLUSION: In a 12-week cross-over feasibility study, TRE was a safe and feasible intervention. Recruitment was challenging and with limited numbers, the TRE group showed a decrease in HbA1c and anthropometric indices compared to the 'ad libitum' group. TRIAL REGISTRATION: NCT05126199.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.